Skip to main content
main-content

Spondyloarthropathies

Psoriatic arthritis

11-01-2019 | Psoriatic arthritis | Editorial | Article

Screening psoriasis patients for development of psoriatic arthritis

Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

Author:
Vinod Chandran

Screening psoriasis patients for development of psoriatic arthritis

As with many rheumatic diseases, diagnosis of psoriatic arthritis is often delayed, contributing to poor quality of life and worse long-term outcomes. Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

03-01-2019 | Psoriatic arthritis | News

Support for methotrexate use in PsA patients

Findings from an observational study suggest that methotrexate treatment, with a dose-escalation strategy targeting remission, improves the joint and skin manifestations of psoriatic arthritis.

Source:

Rheumatology 2018; doi:10.1093/rheumatology/key369

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

Source:

Arthritis Res Ther 2018; doi:10.1186/s13075-018-1764-z

19-12-2018 | Psoriatic arthritis | News

News in brief

Abatacept may improve PROs in PsA patients

Treatment with abatacept is associated with improvements in patient-reported outcomes among individuals with psoriatic arthritis, study findings suggest.

Recognizing and managing cardiovascular risk in PsA patients

medwireNews speaks to Lihi Eder about why patients with psoriatic arthritis have elevated cardiovascular risk, and what can be done to mitigate it.

18-12-2018 | Psoriatic arthritis | Feature | Article

Recognizing and managing cardiovascular risk in PsA patients

medwireNews speaks to Lihi Eder about why patients with psoriatic arthritis have elevated cardiovascular risk, and what can be done to mitigate it.

ACR/NPF guidelines for the treatment of PsA published

The American College of Rheumatology and the National Psoriasis Foundation have issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active psoriatic arthritis.

10-12-2018 | Psoriatic arthritis | Highlight | News

ACR/NPF guidelines for the treatment of PsA published

The American College of Rheumatology and the National Psoriasis Foundation have issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active psoriatic arthritis.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40726
Arthritis Care Res 2018; doi:10.1002/acr.23789
J Psoriasis Psoriatic Arthritis 2018; doi:10.1177/2475530318812244

23-11-2018 | Psoriatic arthritis | Article

Assessing disease activity in psoriatic arthritis: A literature review

Tucker LJ et al. Rheumatol Ther 2018. doi: 10.1007/s40744-018-0132-4

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

15-11-2018 | Etanercept biosimilar | Highlight | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213474

Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Etanercept outperforms methotrexate for PsA

Etanercept has greater efficacy than methotrexate for the treatment of psoriatic arthritis, suggest phase III trial results presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | News

Post-hoc analysis supports further investigation of ustekinumab in PsA-associated spondylitis

Treatment with ustekinumab may be beneficial for some patients with psoriatic arthritis and spondylitis, suggests a post-hoc subgroup analysis of the PSUMMIT 1 and 2 trials.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | Article

From the Editorial Board: Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

24-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | News

Etanercept outperforms methotrexate for PsA

Etanercept has greater efficacy than methotrexate for the treatment of psoriatic arthritis, suggest phase III trial results presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

24-10-2018 | Cardiovascular disease | ACR/ARHP 2018 | Video

Looking to collaborative models of care to improve primary prevention of CVD in patients with inflammatory arthritis

Lihi Eder describes a new model of care based on collaboration between cardiologists and rheumatologists to better manage cardiovascular risk factors in patients with inflammatory arthritis (5:56).

image credits